HSDB-7704 Alvimopan

Alvimopan, also known as HSDB-7704 and LY246736, is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal. It was approved in 2008. Alvimopan is indicated in people to avoid postoperative ileus following partial large or small bowel resection with primary anastomosis. Alvimopan accelerates the gastrointestinal recovery period as defined by time to first bowel movement or flatus.

Properties:
Density: 1.166g/cm3
Melting Point: 210-213ºC
Boiling Point: 684.1ºC at 760mmHg
Flash Point: 367.5ºC

Opioid Receptor Inhibitors Related Products:

JTC-801; Naltrexone HCl; Racecadotril; Trimebutine Maleate Salt; Trimebutine

[1]. NCBI BioAssay: 325959

[2]. Cassel JA, et al. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005 Sep 27;520(1-3):29-36.

[3]. Viscusi ER, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006 Jan;20(1):64-70.